Streetbeat News

Products Services

ARQT

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has presented new data from its ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis. The data shows significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicle. The results were presented at the EADV Congress held in Berlin. The company's Chief Medical Officer, Patrick Burnett, stated that the data suggests roflumilast foam may be an important topical treatment option.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:04 pm

MASI

Masimo Corporation has announced that its ORi has been granted De Novo by the FDA, making it the first noninvasive and continuous parameter to provide insight into hyperoxia under supplemental oxygen. The product will be launched in the U.S. at ANESTHESIOLOGY 2023 this weekend.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:04 pm

FOXO

FOXO Technologies Inc. (NYSE:FOXO) has received an Issue Notification from the United States Patent & Trademark Office (USPTO) for a patent that uses machine learning to enable the commercialization of epigenetic biomarkers. This builds on previous Notices of Allowance issued by the USPTO for two related patents. The patents support the use of machine learning in estimating health aspects and filling in missing or unreliable epigenetic values. The company has generated epigenetic data for over 13,000 individuals to support these patents.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:02 pm

CMCSA

Comcast Corporation has expanded its broadband network to Pelahatchie, Mississippi, providing residents with access to the Xfinity 10G network and a full suite of Xfinity services.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:02 pm

MRK

Merck & Company has received a positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) for its drug KEYTRUDA, in combination with chemotherapy, as a first-line treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma expressing PD-L1 (CPS ≥1).

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 11:48 am

AMLX

Amylyx Pharmaceuticals has received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on its marketing authorisation application for AMX0035 for the treatment of ALS in the European Union. The final decision from the European Commission is expected by the end of 2023. The PHOENIX Phase 3 trial topline results are on track for mid-2024.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 11:46 am

AMD

BABA

NVDA

Alibaba's stock is trading lower due to concerns about China's economic rebound as producer and consumer prices in mainland China missed market expectations. The U.S. is preparing to close a loophole that allowed Chinese companies to access American AI chips through overseas units, which could impact Nvidia and Advanced Micro Devices. On a positive note, Alibaba's logistics arm, Cainiao Network, launched a half-day express delivery service in collaboration with Tmall Supermarket in Beijing.

Portfolio Pulse from Anusuya Lahiri

October 13, 2023 | 11:45 am

PFE

The Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorization in the European Union for Elrexfio, a treatment for adults with relapsed and refractory multiple myeloma. The news may impact Pfizer Inc. (PFE), which could be mentioned in the article.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 11:30 am

USAP

Universal Stainless & Alloy Products (USAP) has announced an immediate base price increase of 5% to 10% on its premium products. Current material and energy surcharges will remain in effect.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 11:12 am

AMZN

XRPUSD

Brendan Berry, Head of Payments Product Management at Ripple, is focusing on improving cross-border payment experience for Ripple's enterprise clientele. His responsibilities include overseeing development of product platform, architecture, and both front-end and back-end systems. Berry's team is working on Ripple's On-Demand Liquidity crypto-enabled cross-border payment product. Prior to Ripple, Berry worked at Patagonia, Slack, and Amazon, where he developed innovative tools and products for Prime Now/Fresh's selection offerings.

Portfolio Pulse from Murtuza Merchant

October 13, 2023 | 11:11 am